Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 2/2015

01-02-2015 | Review Article

Current Drug Treatment of Hyperlipidemia in Older Adults

Authors: Dave L. Dixon, Krista L. Donohoe, Kelechi C. Ogbonna, Sarah M. Barden

Published in: Drugs & Aging | Issue 2/2015

Login to get access

Abstract

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death, especially in older adults. Managing modifiable risk factors (e.g., hyperlipidemia, hypertension) remains the primary approach to prevent ASCVD events and ASCVD-related mortality. Statins are generally considered one of the most effective approaches to reduce ASCVD risk, especially for secondary prevention, yet remain underutilized in older adults. The evidence to support statin therapy in older adults is less robust than in their younger counterparts, especially in individuals aged 75 years and older. Recent lipid guidelines have raised this concern, yet statin therapy is recommended in ‘at risk’ older adults. Determining which older adults should receive statin therapy for primary prevention of ASCVD is challenging, as the currently available risk estimation tools are of limited use in those aged over 75 years. Furthermore, non-statin therapies have been de-emphasized in recent clinical practice guidelines and remain understudied in the older adult population. This is unfortunate given that older adults are less likely to tolerate moderate- to high-intensity statins. Non-statin therapies could be viable options in this population if more was understood about their ability to lower ASCVD risk and safety profiles. Nevertheless, lipid-lowering agents remain an integral component of the overall strategy to reduce atherogenic burden in older adults. Future research in this area should aim to enroll more older adults in clinical trials, determine the utility of ASCVD risk estimation for primary prevention, and investigate the role of non-statin therapies in this population.
Literature
1.
2.
United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population Ageing 2013. ST/ESA/SER.A/348.
3.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
4.
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.CrossRefPubMed
5.
Gaw A. The care gap: underuse of statin therapy in the elderly. Int J Clin Pract. 2004;58(8):777–85.CrossRefPubMed
6.
Reiner Z, Catapano AL, Backer GD, et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769–818.CrossRefPubMed
7.
Grundy SM, Arai H, Barter P, et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipidol. 2014;8(1):29–60.CrossRef
8.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45.CrossRefPubMed
9.
Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473–88.CrossRefPubMed
10.
Goff DC, Lloyd-Jones DM, Bennett G, et al. ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013;2014(129):S49–73.
11.
Muntner P, Safford MM, Cushman M, et al. Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129:266–7.CrossRefPubMed
12.
Koller MT, Steyerberg EW, Wolbers M. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J. 2007;154(1):87–93.CrossRefPubMed
13.
Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.CrossRefPubMedCentralPubMed
14.
Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85.CrossRefPubMed
15.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.CrossRefPubMed
16.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.CrossRef
17.
Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488–96.CrossRefPubMedCentralPubMed
18.
Nakaya N, Mizuno K, Ohashi Y, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging. 2011;28:681–92.CrossRefPubMed
19.
Shepherd J, Blauw GJ, Murphy MB, PROSPER study group, PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.CrossRefPubMed
20.
Bruckert E, Lievre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol. 2003;12:225–31.CrossRefPubMed
21.
Collier DJ, Poulter NR, Dahlof B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens. 2011;29:592–9.CrossRefPubMed
22.
Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29:2378–84.CrossRefPubMed
23.
Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090–9.CrossRefPubMed
24.
Alonzo CB. Myths and facts concerning the use of statins in very old patients. Cardiovasc Hematol Disord Drug Targets. 2011;11(1):17–23.CrossRefPubMed
25.
Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37–45.CrossRefPubMed
26.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.CrossRefPubMed
27.
Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40(4):1405–9.CrossRefPubMed
28.
Pacala JT, McBride PE, Gray SL. Management of older adults with hypercholesterolemia. Drugs Aging. 1994;4(5):366–78.CrossRefPubMed
29.
Sue Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342–56.CrossRefPubMed
30.
Barry PJ, Gallagher P, Ryan C, et al. START (screening tool to alert doctors to the right treatment)—an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36:632–8.CrossRefPubMed
31.
Holmes HM, Haley C, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166:605–9.CrossRefPubMed
32.
Mitnitski AB, Graham JE, Mogilner AJ, et al. Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatrics. 2002;2(1). doi:10.​1186/​1471-2318-2-1.
33.
Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46:549–57.CrossRefPubMed
34.
Padala KP, Padala PR, McNeilly DP, et al. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother. 2012;10:296–302.CrossRefPubMed
35.
36.
McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C–94C.CrossRefPubMed
37.
Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010;50(1):114–8.CrossRefPubMed
38.
Thompson PD, Gadaleta PA, Yurgalevitch S, et al. Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism. 1991;40(12):1333–6.CrossRefPubMed
39.
40.
Wei MY, Ito MK, Cohen JD, et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.CrossRefPubMed
41.
Jacobson TA. NLA task force on statin safety—2014 update. J Clin Lipidol. 2014;8(3 Suppl):S1–4.CrossRef
42.
Phillips PS, Haas RH, Bannykh S, Scripps Mercy Clinical Research Center, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–5.CrossRefPubMed
43.
Phillips PS, Haas RH. Observations from a statin myopathy clinic. Arch Intern Med. 2006;166:1232–3 (author reply 1233).CrossRefPubMed
44.
Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.CrossRefPubMed
45.
46.
El-Salem K, Ababneh B, Rudnicki S, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44:877–81.CrossRefPubMed
47.
Cohen JD, Brinton EA, Ito MK, et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–15.CrossRefPubMed
48.
Ganga HV, Slim HB, Thompson PD. Systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6–15.CrossRefPubMed
49.
Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71.CrossRefPubMed
50.
51.
Neal RC, Ferdinand KC, Ycas J, et al. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med. 2009;122:73–8.CrossRefPubMed
52.
Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603.CrossRefPubMedCentralPubMed
53.
Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367(9518):1262–70.CrossRefPubMed
54.
55.
Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37:231–6.CrossRefPubMedCentralPubMed
56.
Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989–96.CrossRefPubMed
57.
Cutler N, Sramek J, Veroff A, et al. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39:333–6.CrossRefPubMedCentralPubMed
58.
Gengo F, Cwudzinski D, Kinkel P, et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18:209–14.CrossRefPubMed
59.
Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc. 1997;45:8–14.PubMed
60.
Gibellato MG, Moore JL, et al. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med. 2001;72:805–12.PubMed
61.
Golomb BA, Dimsdale JE, White HL, et al. Do low dose statins affect cognition? Results of the UCSD Statin Study. Circulation. 2006;114:2–289.CrossRef
62.
Summers MJ, Oliver KR, Coombes JS, et al. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy. 2007;27:183–90.CrossRefPubMed
63.
Berk-Planken I, de Konig I, Stolk R, et al. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25:1250–1.CrossRefPubMed
64.
Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–67.CrossRef
65.
Parale GP, Baheti NN, Kulkarni PM, et al. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006;62:259–65.CrossRefPubMed
66.
Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538–46.CrossRefPubMed
67.
Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823–9.CrossRefPubMed
68.
Galatti L, Polimeni G, Salvo F, et al. Shortterm memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26:1190–2.CrossRefPubMed
69.
Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767–9.CrossRefPubMed
70.
Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40:1880–3.CrossRefPubMed
71.
Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871–80.CrossRefPubMed
72.
Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S5–16.CrossRefPubMed
73.
Johnson-Anuna LN, Eckert GP, Keller JH, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther. 2005;312:786–93.CrossRefPubMed
74.
Thelen KM, Rentsch KM, Gutteck U, et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther. 2006;316:1146–52.CrossRefPubMed
75.
Tsuji A, Saheki A, Tamai I, et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood–brain barrier. J Pharmacol Exp Ther. 1993;267:1085–90.PubMed
76.
Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(Suppl Guidelines):S265–80.PubMed
77.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.CrossRefPubMed
78.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis. JAMA. 2011;305:2556–64.CrossRefPubMed
79.
Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57:1535–45.CrossRefPubMed
80.
Maki KC, Ridker PM, Brown WV, et al. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S17–29.CrossRefPubMed
81.
Wallace JI. Management of diabetes in the elderly. Clin Diabetes. 1999;17(1):19–25.
82.
Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127(9):788–95.CrossRefPubMed
83.
Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319(1):24–33.CrossRefPubMed
84.
85.
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardio. 2002;40:567–72.CrossRef
86.
The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366(9500):1849–61.CrossRef
87.
88.
Zetia® [package insert]. Whitehouse Station: Merck & Co., Inc; 2013.
89.
Liptruzet® [package insert]. Whitehouse Station: Merck & Co., Inc; 2013.
90.
Khanderia U, Regal RE, Rubenfire M, et al. The ezetimibe controversy: implications for clinical practice. Ther Adv Cardiovasc Dis. 2011;5(4):199–208.CrossRefPubMed
91.
Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014;168(2):205–212.e1.
92.
The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.CrossRef
93.
The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12.CrossRef
94.
Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Assocation. J Clin Lipidol. 2013;7(5):484–525.CrossRefPubMed
95.
Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6 Suppl 1):S3–18.CrossRef
96.
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341(6):410–8.CrossRefPubMed
97.
98.
Murrow JR. The role of nonstatin therapy in managing hyperlipidemia. Am Fam Physician. 2010;82(9):1056–7.PubMed
99.
Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3- fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–57.CrossRefPubMed
100.
Lovaza® [package insert]. Research Triangle Park: GlaxoSmithKline; 2014.
101.
Vascepa® [package insert]. Bedminster: Amarin Pharma Inc.; 2013.
102.
103.
The ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–18.CrossRef
Metadata
Title
Current Drug Treatment of Hyperlipidemia in Older Adults
Authors
Dave L. Dixon
Krista L. Donohoe
Kelechi C. Ogbonna
Sarah M. Barden
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2015
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-015-0240-6

Other articles of this Issue 2/2015

Drugs & Aging 2/2015 Go to the issue

Original Research Article

Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United States

Systematic Review

Systematic Review and Meta-Analysis: What Is the Evidence for Oral Iron Supplementation in Treating Anaemia in Elderly People?

Systematic Review

Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect

Original Research Article

Impact of Multiple Low-Level Anticholinergic Medications on Anticholinergic Load of Community-Dwelling Elderly With and Without Dementia

Current Opinion

Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines

Review Article

Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Adults with Intellectual Disability
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits